AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Anteris Posts Q3 2025 Results, Secures Key Approvals for PARADIGM Trial Launch
ByAinvest
Wednesday, Nov 12, 2025 7:09 pm ET1min read
Anteris Technologies reported Q3 2025 financial results, with net operating cash outflows of $59.3 million. R&D expenses reached $16.8 million, driven by IDE-related work and manufacturing upscaling. Selling, general & administrative expenses were $5.8 million. Cash and cash equivalents stood at $9.1 million. The company secured key approvals to launch the PARADIGM trial of the DurAVR transcatheter heart valve, including FDA approval in the US and Danish approval in Europe.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet